Published in Nature on September 07, 1995
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 3.66
Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J (2003) 3.62
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Myeloproliferative disorders. Blood (2008) 3.37
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway. Genes Dev (1998) 2.47
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol (2011) 2.44
B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med (2010) 2.42
Human genetic susceptibility to infectious disease. Nat Rev Genet (2012) 2.25
The Janus kinases (Jaks). Genome Biol (2004) 2.18
Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J (1999) 2.09
Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol (2009) 1.92
Inborn errors of human JAKs and STATs. Immunity (2012) 1.90
Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res (2011) 1.78
A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest (2005) 1.77
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A (1996) 1.75
Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol Cell Biol (2004) 1.54
The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A (1997) 1.53
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol (1997) 1.52
Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci U S A (2010) 1.50
Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci U S A (1997) 1.47
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol (2000) 1.38
Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest (2004) 1.33
Educational paper. The expanding clinical and immunological spectrum of severe combined immunodeficiency. Eur J Pediatr (2011) 1.33
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
Polarity determination in the Drosophila eye: a novel role for unpaired and JAK/STAT signaling. Genes Dev (1999) 1.29
IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol (2009) 1.28
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol (2000) 1.27
Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol (2015) 1.27
Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med (1998) 1.24
Interleukin 7 receptor control of T cell receptor gamma gene rearrangement: role of receptor-associated chains and locus accessibility. J Exp Med (1998) 1.18
Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol (2013) 1.17
Severe combined immunodeficiencies (SCID). Clin Exp Immunol (2000) 1.17
The interleukin 7 receptor is required for T cell receptor gamma locus accessibility to the V(D)J recombinase. J Exp Med (2000) 1.16
Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis (2004) 1.16
Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol (2012) 1.15
T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood (2006) 1.15
Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J (1999) 1.15
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol (2012) 1.12
Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med (1997) 1.11
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol (2015) 1.11
Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09
IL-7 in human health and disease. Semin Immunol (2012) 1.08
Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest (1998) 1.05
Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol (2014) 1.05
Advances in immunosuppression for renal transplantation. Nat Rev Nephrol (2010) 1.05
Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets (2010) 1.04
The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res (2002) 1.03
Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol Cell Biol (2004) 1.01
Interleukin 7 independent development of human B cells. Proc Natl Acad Sci U S A (1996) 1.01
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum (2012) 1.01
IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol (2009) 1.00
Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol Cell Biol (2000) 0.99
The mosquito microbiota influences vector competence for human pathogens. Curr Opin Insect Sci (2014) 0.99
The molecular pathology of primary immunodeficiencies. J Mol Diagn (2004) 0.98
Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J Clin Invest (2002) 0.98
JAK2 inhibitors: what's the true therapeutic potential? Blood Rev (2010) 0.97
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol (2014) 0.97
Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood (2005) 0.96
Cytokine signaling: birth of a pathway. J Immunol (2011) 0.95
The molecular regulation of Janus kinase (JAK) activation. Biochem J (2014) 0.95
STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT (2013) 0.94
The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells. J Immunol (2013) 0.91
The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res (2015) 0.91
Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol (2012) 0.90
A multitude of kinases--which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am (2010) 0.90
Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest (1997) 0.90
Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J (1996) 0.89
From murine to human nude/SCID: the thymus, T-cell development and the missing link. Clin Dev Immunol (2012) 0.89
Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol (1997) 0.88
Crucial role of Jak3 in negative selection of self-reactive T cells. J Exp Med (1997) 0.87
A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation. J Biol Chem (2011) 0.87
Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res (1999) 0.87
Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. J Clin Immunol (1997) 0.87
Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy. J Clin Immunol (2014) 0.86
Differential requirement of the cytoplasmic subregions of gamma c chain in T cell development and function. Proc Natl Acad Sci U S A (2000) 0.86
Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases. PLoS One (2012) 0.86
Severe combined immunodeficiency--molecular pathogenesis and diagnosis. Arch Dis Child (2001) 0.85
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med (1996) 0.84
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Current concepts in the management of rheumatoid arthritis. Korean J Intern Med (2016) 0.84
Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. Cancer Invest (2009) 0.83
Identification of molecular switch regulating interactions of Janus kinase 3 with cytoskeletal proteins. J Biol Chem (2012) 0.83
Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol (2012) 0.83
T Cell Genesis: In Vitro Veritas Est? Trends Immunol (2016) 0.82
Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Curr Top Med Chem (2013) 0.82
Interleukin-2 signaling and inherited immunodeficiency. Am J Hum Genet (1999) 0.82
Searching for genes involved in the pathogenesis of primary immunodeficiency diseases: lessons from mouse knockouts. J Clin Immunol (1997) 0.81
Janus kinase 3: the controller and the controlled. Acta Biochim Biophys Sin (Shanghai) (2011) 0.81
Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation. Proc Natl Acad Sci U S A (1997) 0.81
Gene hunting in the genomic era: approaches to diagnostic dilemmas in patients with primary immunodeficiencies. J Allergy Clin Immunol (2013) 0.81
Human lymphoid development in the absence of common γ-chain receptor signaling. J Immunol (2014) 0.80
Tyrosine kinases in rheumatoid arthritis. J Inflamm (Lond) (2011) 0.80
Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed (2001) 0.80
Atypical X-linked SCID phenotype associated with growth hormone hyporesponsiveness. Clin Exp Immunol (2002) 0.80
A novel mutant gammac chain from a patient with typical phenotype of X-linked severe combined immunodeficiency (SCID) has partial signalling function for mediating IL-2 and IL-4 receptor action. Clin Exp Immunol (1999) 0.80
Screening for severe combined immunodeficiency in neonates. Clin Epidemiol (2013) 0.79
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med (1999) 10.62
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell (2000) 9.99
A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med (1997) 9.73
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Jaks and STATs: biological implications. Annu Rev Immunol (1998) 7.18
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol (1998) 5.32
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A (2001) 4.76
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (1993) 4.39
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science (1994) 3.46
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 3.43
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature (1994) 3.31
Partial V(D)J recombination activity leads to Omenn syndrome. Cell (1998) 3.18
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science (1995) 3.15
Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet (2000) 3.12
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
Ilizarov treatment of tibial nonunions with bone loss. Clin Orthop Relat Res (1989) 2.71
Pars interarticularis fenestration in the treatment of foraminal lumbar disc herniation: a further surgical approach. Neurosurgery (1998) 2.68
Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev (1992) 2.67
Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A (1995) 2.52
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood (2001) 2.50
Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A (2001) 2.39
Bacteriostatic and bactericidal activities of various antibiotics against Bacteroides fragilis. Antimicrob Agents Chemother (1973) 2.34
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells (1999) 2.28
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood (2000) 2.24
Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol (2008) 2.23
IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol (2001) 2.13
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun (2013) 2.10
Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med (2001) 2.06
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest (2001) 2.05
The inositol 1,4,5,-trisphosphate receptor in cerebellar Purkinje cells: quantitative immunogold labeling reveals concentration in an ER subcompartment. J Cell Biol (1990) 2.03
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J Immunol (1984) 2.01
IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J Immunol (2000) 2.01
Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A (1994) 1.84
Type 1 IFNs and regulation of TH1 responses: enigmas both resolved and emerge. Nat Immunol (2000) 1.84
Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol (2001) 1.81
Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med (1995) 1.78
SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol (1999) 1.69
Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol (1996) 1.68
TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol (2000) 1.68
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet (2001) 1.68
Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature (2000) 1.65
Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol (2001) 1.64
Connective tissue proteins and phagocytic cell function. Laminin enhances complement and Fc-mediated phagocytosis by cultured human macrophages. J Exp Med (1985) 1.62
Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell (2001) 1.61
Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol (1999) 1.61
Intracranial-pressure changes following head injury. Lancet (1970) 1.60
Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol (2000) 1.59
The N-terminal domain of human DNA ligase I contains the nuclear localization signal and directs the enzyme to sites of DNA replication. EMBO J (1995) 1.59
Short rib-polydactyly syndrome and pericentric inversion of chromosome 4. Am J Med Genet (1994) 1.56
High-yield expression and functional analysis of Escherichia coli glycerol-3-phosphate transporter. Biochemistry (2001) 1.56
The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A (1997) 1.53
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol (2001) 1.53
Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol (2000) 1.52
The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) (2000) 1.52
A new nucleotide-excision-repair gene associated with the disorder trichothiodystrophy. Am J Hum Genet (1993) 1.51
Fusarium graminearum A 3/5 as a novel host for heterologous protein production. Biotechnology (N Y) (1995) 1.51
Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol (2001) 1.50
A novel hnRNP protein (HAP/SAF-B) enters a subset of hnRNP complexes and relocates in nuclear granules in response to heat shock. J Cell Sci (1999) 1.50
Medium-chain acyl-CoA dehydrogenase deficiency. Diagnosis by stable-isotope dilution measurement of urinary n-hexanoylglycine and 3-phenylpropionylglycine. N Engl J Med (1988) 1.49
Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII). J Immunol (1991) 1.48
Xeroderma pigmentosum complementation group H falls into complementation group D. Mutat Res (1991) 1.48
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. Eur J Cancer (1994) 1.47
Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci U S A (1997) 1.47
Spontaneous NBT reduction by monocytes as a marker of disease activity in children with histiocytosis. Br J Haematol (1990) 1.45
CARBON AND NITROGEN BALANCE OF CHLORELLA DURING GROWTH. Plant Physiol (1949) 1.44
European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet (1990) 1.44
Loose-patch recordings of single quanta at individual hippocampal synapses. Nature (1997) 1.43
Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr (1994) 1.42
Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol (1996) 1.41
Early outcome of liver transplantation performed with organs procured from brain death donors with transient or sustained cardio-circulatory collapse. Minerva Anestesiol (2014) 1.40
Human serum albumin: twenty-three genetic variants and their population distribution. Ann Hum Genet (1973) 1.40
A mutant cytochrome b5 with a lengthened membrane anchor escapes from the endoplasmic reticulum and reaches the plasma membrane. Proc Natl Acad Sci U S A (1996) 1.40
Programmed bone-marrow donor for a leukaemic sibling, 10 years on. Lancet (1997) 1.39
The reconstitution of cellular immunity after bone marrow transplantation in children. Haematologica (1992) 1.39
Sinus histiocytosis with massive lymphoadenopathy (Rosai-Dorfman disease). Clinico-pathological analysis of a paediatric case. Eur J Pediatr (1992) 1.38
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol (2000) 1.38
Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol (1998) 1.37
The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination. Mol Cell (1999) 1.35
Additional data on the population distribution of human serum albumin genes; three new variants. Ann Hum Genet (1973) 1.35
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet (1996) 1.35